Chlorogenic Acid Functions as a Novel Agonist of PPAR<svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" style="vertical-align:-4.5268pt" id="M1" height="12.3952pt" version="1.1" viewBox="-0.0657574 -7.8684 8.76089 12.3952" width="8.76089pt"><g transform="matrix(.017,0,0,-0.017,0,0)"><path id="g113-225" d="M478 372C478 418 458 448 431 448C409 448 389 431 389 410C389 404 391 400 394 395C398 388 406 371 406 348C406 253 308 122 251 51H249C254 122 249 257 231 336C212 421 189 448 159 448C126 448 75 412 23 327L48 306C83 354 103 371 115 371C125 371 134 360 144 334C185 224 192 64 183 -19C146 -100 116 -202 110 -244L125 -261C154 -259 208 -234 222 -220C222 -194 225 -84 235 -23C247 -3 273 36 308 79C379 165 478 288 478 372Z"/></g></svg>2 during the Differentiation of Mouse 3T3-L1 Preadipocytes

Peng, Shu-guang; Pang, Yi-lin; Zhu, Qi; Kang, Jing-he; Liu, Ming-xin; Wang, Zheng

doi:https://doi.org/10.1155/2018/8594767

BioMed Research International

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusions Data Availability Conflicts of Interest Authors’ Contributions Acknowledgments References Copyright Related Articles

Special Issue

Impact of Nutritional and Environmental Factors on Inflammation, Oxidative Stress, and the Microbiome 2019

View this Special Issue

Research Article | Open Access

Volume 2018 | Article ID 8594767 | https://doi.org/10.1155/2018/8594767

Chlorogenic Acid Functions as a Novel Agonist of PPAR2 during the Differentiation of Mouse 3T3-L1 Preadipocytes

Shu-guang Peng,^1,2,3Yi-lin Pang,¹Qi Zhu,¹Jing-he Kang,⁴Ming-xin Liu,¹and Zheng Wang¹

Guest Editor: Yan Huang

Received12 Sept 2018

Accepted19 Nov 2018

Published03 Dec 2018

Abstract

Rosiglitazone (RG) is a well-known activator of peroxisome proliferator-activated receptor-gamma (PPARγ) and used to treat hyperglycemia and type 2 diabetes; however, its clinical application has been confounded by adverse side effects. Here, we assessed the roles of chlorogenic acid (CGA), a phenolic secondary metabolite found in many fruits and vegetables, on the differentiation and lipolysis of mouse 3T3-L1 preadipocytes. The results showed that CGA promoted differentiation in vitro according to oil red O staining and quantitative polymerase chain reaction assays. As a potential molecular mechanism, CGA downregulated mRNA levels of the adipocyte differentiation-inhibitor gene Pref1 and upregulated those of major adipogenic transcriptional factors (Cebpb and Srebp1). Additionally, CGA upregulated the expression of the differentiation-related transcriptional factor PPARγ2 at both the mRNA and protein levels. However, following CGA intervention, the accumulation of intracellular triacylglycerides following preadipocyte differentiation was significantly lower than that in the RG group. Consistent with this, our data indicated that CGA treatment significantly upregulated the expression of lipogenic pathway-related genes Plin and Srebp1 during the differentiation stage, although the influence of CGA was weaker than that of RG. Notably, CGA upregulated the expression of the lipolysis-related gene Hsl, whereas it did not increase the expression of the lipid synthesis-related gene Dgat1. These results demonstrated that CGA might function as a potential PPARγ agonist similar to RG; however, the impact of CGA on lipolysis in 3T3-L1 preadipocytes differed from that of RG.

1. Introduction

Diabetes mellitus is a chronic degenerative metabolic disease that seriously affects human health and has reached epidemic proportions over the last 30 years [1]. Concomitant with the prevalence of obesity and increased lifespan in industrial countries, the incidence of type 2 diabetes has risen rapidly worldwide [2], with the number of people suffering from diabetes globally expected to rise to >600 million within the next 25 years [3]. Currently, China has the highest number of affected individuals, of whom 90% are afflicted with type 2 diabetes mellitus [4, 5]. A primary treatment strategy for type 2 diabetes relies upon improving insulin sensitivity, such as with the thiazolidinedione-class drug rosiglitazone (RG), a powerful insulin sensitizer. As a ligand of the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPARγ), RG promotes the transcription of downstream genes of PPARγ [2]; however, long-term use of RG reportedly causes severe cardiovascular events and increased bone-fracture rates [6, 7]. Additionally, RG causes a significant weight increase in overweight subjects with type 1 diabetes [8]. Therefore, the safety of RG has been challenged. Accordingly, although RG is still utilized to treat patients suffering from type 2 diabetes in China [9, 10], it has been withdrawn from the European market [11]. To address this issue, researchers have focused on identifying new PPARγ agonists [11, 12] and insulin sensitizers as RG substitutes.

Many types of phenols have been advocated as natural remedies (e.g., eugenol or capsaicins) or dietary supplements (e.g., methoxypsoralen). The burden, metabolism, and biological effects of these dietary polyphenols are gradually gaining scientific and public attention and have been well studied, with results clarifying the margin of safety between a safe dose and the minimal dose necessary to produce significant adverse effects [13–15].

Epidemiological studies demonstrated that chlorogenic acid (CGA), a type of dietary polyphenol present in high quantities in plants and constituting the main active ingredient in many fruits, vegetables, and plants [16, 17], possesses numerous pharmacological activities, including those associated with antioxidative [18], anticancer [19–21], hypolipidemic [22], antihypertensive [23], anti-inflammatory [24], and hypoglycemic effects. Moreover, studies reported effects related to anti-insulin resistance and obesity [25], and protection against plant pathogenic fungi [26], as well as antimicrobial effects [27], inhibition of bile-duct ligation-induced liver injury [28], and attenuation of lipopolysaccharide-induced acute kidney injury [29]. Furthermore, CGA reportedly exhibits neuroprotective activity [30], and hypoxia-induced angiogenesis [31], and extends the lifespan of Caenorhabditis elegans [32]. Accumulating studies demonstrate that CGA exhibits antiobesity function by adjusting obesity-related adipokine levels, upregulating β-oxidation of fatty acids in the liver, and downregulating fatty acid and cholesterol biosynthesis in obese mice fed a high-fat diet (HFD) [16, 33]. Our previous study showed that CGA improved obesity-related metabolic disorders by upregulating Pparg2 expression and inhibiting the nuclear factor (NF)-κB-signaling pathway in the adipose tissue of obese rats induced by a HFD [17]. Therefore, we hypothesized that CGA might function as a PPARγ agonist similar to RG, yet play a different regulatory role in preadipocyte differentiation to adipocytes.

Here, we used 3T3-L1 cells as an experimental model to explore the roles of CGA on lipogenesis. Specifically, we assessed the influence of CGA on 3T3-L1 cell proliferation and the expression of transcription factors [Pparg2, CCAAT/enhancer binding protein beta (Cebpb), and sterol regulatory element-binding protein (Srebp)1] and the key adipocyte-differentiation-related gene preadipocyte factor 1 (Pref1) during adipocyte differentiation. These results associated with CGA-mediated differentiation of mouse 3T3-L1 cells provide meaningful referential data for the rational use of CGA and the improvement of dietary structure.

2. Materials and Methods

2.1. Chemicals and Materials

Dulbecco’s modified Eagle medium (DMEM), fetal bovine serum (FBS), streptomycin, and penicillin were acquired from Thermo Fisher Scientific (Waltham, MA, USA). CGA (⩾95% purity), rosiglitazone (RG; ⩾98% purity), and GW9662 (⩾99% purity) were purchased from Sigma-Aldrich (St. Louis, MO, USA), dissolved in dimethyl sulfoxide formulated as a 10 mM stock solution, and stored at -20°C. The rabbit monoclonal antibody against PPARγ (81B8) was purchased from Cell Signaling Technology (Danvers, MA, USA), and antibodies against β-actin, proliferating cell nuclear antigen (PCNA), horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG, and HRP-conjugated goat anti-rabbit IgG were purchased from Proteintech (Rosemont, IL, USA).

2.2. Cell Culture

Undifferentiated mouse 3T3-L1 preadipocytes were purchased from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China), and cells were passaged 17 times. 3T3-L1 cells were cultured in high-glucose DMEM containing 10% FBS and 1% penicillin/streptomycin and incubated at 37°C in an atmosphere with 5% CO₂.

2.3. Cell-Viability Analysis

3T3-L1 cells were seeded into 96-well plates at a density of 5 × 10³ cells/well and incubated overnight. Cells were then incubated with different concentrations of CGA, and after 24 h, 48 h, and 72 h, cell viabilities were determined by counting living and dead cells using the trypan blue dye (0.05% solution)-exclusion method analyzed with a Bright-Line Hemacytometer (Sigma-Aldrich, USA) and cell counting kit (CCK)-8 (Dojindo, Kumamoto, Japan), respectively. After a 4 h incubation with 10 μL CCK-8 reagent, cell viability was calculated by measuring the optical density at 450 nm (Varioskan Flash; Thermo Fisher Scientific).

2.4. Induced Differentiation of Mouse 3T3-L1 Preadipocytes

3T3-L1 cells were seeded into a 6-well plate at a concentration of 2 × 10⁵ cells/well. Upon reaching ~90% confluence, the medium was replaced with fresh high-glucose DMEM containing 10% FBS and 1% penicillin/streptomycin, followed by incubation at 37°C in 5% CO₂ for 2 days and culture in cell-differentiation medium 1 (fresh high-glucose DMEM containing 10% FBS, 0.5 mM 3-isobutyl-1-methylxanthine, 1 μM dexamethasone, and 5 μg/mL insulin) containing 20 μM CGA, RG (positive control group), or GW9662 (negative control group). The differentiation time was calculated from the day at which the medium was changed. After 2 days, the medium was exchanged with cell-differentiation medium 2 (fresh high-glucose DMEM containing 10% FBS and 5 μg/mL insulin) containing the same combination of chemicals described. After another 2 days, cell-differentiation medium 2 was removed and replaced with cell-differentiation maintenance medium (CDMM) containing fresh high-glucose DMEM and 10% FBS. CDMM was changed every 2 days until the majority of the preadipocytes had differentiated into adipocytes and obvious lipid droplets were observed in the mature fat cells.

2.5. Oil Red O (ORO) Staining

The lipid accumulation in differentiated 3T3-L1 cells was observed by ORO staining on day (D)4, D6, D8, and D10 of differentiation. Cells were fixed with 4% formaldehyde for 30 min to 60 min after two washes with phosphate-buffered saline (PBS) and stained in ORO solution for 1 h after another two washes, followed by several rinses with 75% alcohol to remove excess dye. The cells were then washed several times with ultrapure water, and photomicrographs were acquired at 200× magnification using a system incorporated in the DMI3000B inverted microscope (Leica, Wetzlar, Germany).

2.6. Triglyceride Assay

Intracellular triglycerides were evaluated using a triglyceride assay kit (GPO-POD; Applygen Technologies, Beijing, China) according to manufacturer protocol.

2.7. RNA Preparation and Quantitative Real-Time Polymerase Chain Reaction (qPCR)

Total RNA was isolated from test cells using TRIzol reagent (Thermo Fisher Scientific), with 1 μg of each sample RNA used to generate cDNA using a reverse transcription reagent kit with gDNA Eraser (TaKaRa, Dalian, China) as a template for qPCR. Reactions were performed on a Step-One plus qPCR system (Applied Biosystems, Foster City, CA, USA) using SYBR Green qPCR master mix (TaKaRa). The sample was predenatured at 95°C for 30 s, followed by 40 cycles of denaturation at 95°C for 5 s and annealing at 60°C for 30 s. PCR efficiency for the primers ranged from 90% to 110%, and threshold cycle numbers (CT) were recorded for each reaction and normalized against that of β-actin. The primers were designed using Primer 5 software (Premier Biosoft, Palo Alto, CA, USA) and synthesized by Sangon Biotech Co., Ltd. (Shanghai, China) (Table 1).

2.8. Western Blot Analysis

On D0, D2, D4, D6, and D8 of 3T3-L1 cell differentiation, cells were lysed in radio immunoprecipitation assay lysis buffer (Applygen Technologies) supplemented with protease and phosphatase inhibitors on ice for 10 min after ice-cold PBS washes, followed by centrifugation at 12,000 g for 15 min at 4°C and supernatant collection. The nuclear fraction was extracted using a Nuc-Cyto-Mem preparation kit (Applygen Technologies), and protein concentrations were assayed using a BCA assay kit (Beyotime, Beijing, China). Each sample (50 μg protein) was separated by 10% gel electrophoresis before electrophoretic transfer onto polyvinylidene fluoride membranes (Bio-Rad, Hercules, CA, USA). Blots were blocked at room temperature for 2 h in blocking buffer [5% slim milk in Tris-buffered saline containing Tween20 (TBST)] and incubated with primary antibodies specific to PPARγ2 (1:1000), PCNA (1:5000), and β-actin (1:4000) overnight at 4°C. After three washes with TBST, the membrane was incubated with the secondary antibodies [HRP-conjugated anti-rabbit (1:6000) and anti-mouse (1:4000) IgG] at room temperature for 2 h with gentle agitation. Immunoreactive bands were visualized using an enhanced chemiluminescence reagent according to manufacturer instructions (Thermo Fisher Scientific). The optical density was quantified using Quantity One software (Bio-Rad).

2.9. Confocal Microscopy Analysis

On D0, D2, and D8 of 3T3-L1 cell differentiation, cells were rinsed with PBS twice for 5 min and fixed with 4% paraformaldehyde for 10 min, followed by three washes with PBS and permeabilization at room temperature for 30 min with 0.5% Triton X-100. Cells were then rinsed in PBS with Tween20 three times, followed by a blocking step with PBS containing 5% FBS at room temperature for 1 h. Samples were then incubated overnight at 4°C with a 1:100 dilution of anti-PPARγ2, followed by incubation with a secondary BODIPY conjugated goat anti-rabbit antibody (Cell Signaling Technology) at room temperature for 1.5 h. After incubation, cells were rinsed and stained with 4′,6-diamidino-2-phenylindole (DAPI) for 6 min, followed by a series of 5-minute washes. The cells were sealed with an antifluorescence quencher; confocal images were captured using an LSM 7DUO confocal microscope (Carl Zeiss AG, Oberkochen, Germany) and processed using ZEN Lite software (Carl Zeiss AG).

2.10. Statistical Analysis

All values were expressed as the means ± standard error of the mean and analyzed with the SPSS package (v16.0; SPSS, Inc., Chicago, IL, USA). One-way analysis of variance, followed by least-significant difference tests, was used to evaluate significant differences between groups, with a P < 0.05 considered significant.

3. Results

3.1. Effect of CGA on Mouse 3T3-L1 Preadipocyte Proliferation

Cell-counting results showed that CGA influenced 3T3-L1 cell proliferation, with concentrations <50 μM resulting in no significant changes following incubation for 24 h and 48 h. However, increases in the incubation time to 72 h and CGA concentration ⩾50 μM resulted in significant inhibition of proliferation and a decrease in cell viability to 13.7% at 50 μM CGA (Figure 1). These results indicated that CGA displayed dose- and time-dependent effects on cell viability.

3.2. CGA Treatment Promotes Differentiation of 3T3-L1 Preadipocytes

CGA was tested to investigate its ability to promote 3T3-L1 preadipocyte differentiation. We observed the accumulation of lipid droplets in differentiated cells by microscopy on D10 of differentiation, after which morphological changes were detected in RG-treated 3T3-L1 cells, which changed from a predifferentiation spindle-like shape to a round shape following differentiation [Figure 2(A)(a, b)]. Additionally, microscopy analysis of ORO-stained lipid droplets within the cells revealed obvious lipid accumulation in RG- and CGA-treated cells relative to that observed in the control and GW9662-treated groups, although CGA treatment appeared less effective than RG treatment (Figure 2). Moreover, CGA-induced adipocyte morphology differed from that of the RG group (Figure 2).

Figure 2

Comparative effect of chlorogenic acid (CGA) and rosiglitazone (RG) on the differentiation of mouse 3T3-L1 preadipocytes. (A) 3T3-L1 preadipocytes were cultured with or without CGA (20 μM) for 10 days; then cells were stained with ORO. RG was used as a positive control. GW9662 was used as a negative control group (GG). All images are shown at 200 × magnification. (a) Control group (CG); (b) RG group; (c) GG group; (d) CGA group; the arrows in a-d indicate the differentiation of preadipocytes; (B-C) effects of CGA on the expression of lipogenic pathway-related genes during the differentiation process of mouse 3T3-L1 preadipocytes. (B) Plin; (C) Srebp1. Data are shown as the means ± SD (n = 3). ^∗P < 0.05, ^∗∗P < 0.01, ^∗∗∗P < 0.001.

To further evaluate the effect of CGA on 3T3-L1 preadipocyte differentiation, we determined the expression of genes involved in the protection of lipid droplets from lipolysis (perilipin; Plin) [34] and de novo lipogenesis (Srebp1) [35]. Compared with the positive and negative control (GW9662) groups, following CGA intervention, Plin and Srebp1 mRNA levels were significantly upregulated during the differentiation process (Figures 2(B) and 2(C)); however, consistent with ORO-staining results, CGA treatment appeared less effective than RG treatment.

3.3. CGA Treatment Did Not Lead to Accumulation of Excess Intracellular Triacylglyceride (TAG)

We determined TAG content to verify the influence of CGA on 3T3-L1 differentiation after D10. As shown in Figure 3, TAG content was significantly increased (about 2-fold) in 3T3-L1 cells treated with RG relative to that observed in the control group, whereas TAG content in CGA-treated 3T3-L1 cells was significantly decreased relative to that in the RG group (P < 0.05), although not significantly different from that in the control group. Additionally, treatment of differentiated cells with GW9662 (20 μM) decreased triglyceride levels by 42.9% as compared with the control group. These results were consistent with ORO-staining results, in that CGA treatment appeared less effective than RG treatment. These findings indicated that CGA effectively promoted adipocyte differentiation of 3T3-L1 cells, although the accumulation of intracellular TAG following preadipocyte differentiation was significantly lower than that in the RG-treated group.

(a)

(b)

(c)

Figure 3

Chlorogenic acid (CGA) reduced triacylglyceride (TAG) accumulation in differentiated 3T3-L1 cells compared with the rosiglitazone group (RG). (a) Mouse 3T3-L1 preadipocytes were cultured without (control group, CG) or with CGA (20 μM) for 10 days; then the cellular TAG contents were measured using a TAG determination kit. (b-c) Effects of CGA on expression of the lipolysis-related gene Hsl (b) and triacylglycerol synthesis-related gene Dgat1 (c) during the differentiation process of mouse 3T3-L1 preadipocytes. RG was used as a positive control. GW9662 was used as a negative control (GG). CG, control group. Data are shown as the means ± SD (n = 3). ^∗P < 0.05, ^∗∗P < 0.01, ^∗∗∗P < 0.001.

To determine the mechanistic differences between CGA- and RG-induced 3T3-L1 differentiation, we analyzed the mRNA levels of genes involved in lipolysis (hormone-sensitive lipase; Hsl) and triglyceride biosynthesis (diacylglycerol O-acyltransferase 1; Dgat1). CGA treatment significantly increased Hsl expression by 30.9% to 58.1% during the prophase differentiation of 3T3-L1 cells (Figures 3(b) and 3(c)), whereas treatment with 20 μM CGA did not significantly alter Dgat1 mRNA levels during the entire differentiation process relative to those observed in control and GW9662 groups. By contrast, RG treatment upregulated Hsl levels by 44.0% to 93.7% and Dgat1 levels by 12.3% to 57.7% relative to those in control group. These results suggested that the reason CGA did not promote TAG accumulation might have been its upregulation of Hsl (lipolysis) and lack of effect on Dgat1 (lipid synthesis) expression. These findings implied that the influence of CGA on preadipocytes differed from that of RG.

3.4. CGA Treatment Activates Key Genes Involved in Adipocyte Differentiation and the Transcription Factor PPARγ2

To quantify the role of CGA in the expression of key adipogenesis-related genes [Pref1 and retinoid X receptor alpha (Rxra)] and major adipogenic transcription factors (Pparg2 and Cebpb) during adipogenesis, preadipocytes were treated with 20 μM CGA during adipocyte differentiation on D2 to D10, and gene expression was analyzed by qPCR. Following CGA treatment, Pparg2 and Cebpb mRNA levels increased relative to levels in control or GW9662-treated groups, whereas Pref1 mRNA levels decreased during the differentiation process. However, no significant change in Rxra mRNA levels was observed between the CGA-treated and control groups. Also, it is worth noting that the effect of CGA on Pref1, Cebpb, and Pparg2 mRNA levels appeared higher than that observed in the RG-treated group (Figure 4), suggesting that CGA treatment promoted 3T3-L1 cell differentiation to a level similar to that of RG treatment.

(a)

(b)

(c)

(d)

3.5. CGA Upregulates PPARγ2 Protein Levels during Adipocyte Differentiation

Western blot results showed that PPARγ2 levels increased significantly (by 18.42-76.92%) from D2 to D6 of differentiation following RG treatment as compared with levels in the control group (Figure 5). By contrast, CGA treatment resulted in significant increases in PPARγ2 levels in 3T3-L1 cells from D4 relative to those observed in control and GW9662-treated groups. However, on D8, the difference in these levels between the RG-treated and control groups was minimal, whereas those in the CGA group were >90% higher relative to PPARγ2 levels in the control (P < 0.01), GW9662-treated (P < 0.01), and RG-treated groups (P < 0.05), respectively.

(a)

(b)

Figure 5

Chlorogenic acid (CGA) activates PPARγ2 during the differentiation process of mouse 3T3-L1 preadipocytes. (a) Mouse 3T3-L1 preadipocytes were treated with control (control group; CG), rosiglitazone (RG), GW9662 (GG), and CGA for 2, 4, 6, and 8 days, respectively. The samples were lysed and subjected to western blot analysis with indicated antibodies. Left: total cell lysate; Right: nucleus fraction. (b) The intensity of the band was quantified using densitometric imaging. Data are shown as the means ± SD (n = 3). ^∗P < 0.05, ^∗∗P < 0.01.

In the nucleus of 3T3-L1 cells on D2 to D6, PPARγ2 levels in the CGA- and RG-treated groups increased relative to levels in the control and GW9662-treated groups. In particular, the highest PPARγ2 levels in the CGA-treated group appeared on D2 and were >2-fold higher than those in other treatment groups (P < 0.01). However, on D8, PPARγ2 levels in both the RG- and CGA-treated groups were significantly lower (~70%) than that in the control group (P < 0.01) and similar to that in the GW9662-treated group (P > 0.05). These results suggested that CGA treatment promoted adipocyte differentiation through upregulated PPARγ2 mRNA and protein levels.

3.6. CGA Affects the Subcellular Distribution of PPARγ2 during Adipocyte Differentiation

PPARγ2 is found specifically in adipose tissue [36]; however, to evaluate whether CGA affects PPARγ2 subcellular distribution, we investigated the distribution of endogenous PPARγ2 by immunostaining and confocal microscopy of mouse preadipocytes (Figure 6). On D0 and D2, immunostaining revealed PPARγ2 in the nucleus, with RG treatment significantly increasing the green (PPARγ2):blue (nucleus) fluorescence ratio by 65.55% as compared with that of the control group (P < 0.01), whereas no difference was detected between the GW9662-treated and control groups (Figure 6(c)). By contrast, this ratio in the CGA-treated group was significantly (26.71%) higher than that of the control group (P < 0.01) and significantly lower (24.07%) than that of the RG-treated group (P < 0.01) (Figure 6(c)). Figure 6(d) shows a robust enhancement in blue fluorescence intensity on D8 relative to that on D2, suggesting an increased PPARγ2 distribution outside of the nucleus. Although we found no significant difference between the RG-treated and control groups, PPARγ2 levels in the CGA-treated group were slightly higher than those in the other three groups, with green:blue fluorescence ratio 30.17% higher than that of the control group (P < 0.05), 48.6% higher than that of the GW9662-treated group (P < 0.01), and 22.47% higher than that of the RG-treated group (P > 0.05) (Figure 6(e)). These results indicated that CGA and RG promoted PPARγ2 expression and subcellular distribution similarly during adipocyte differentiation.

Figure 6

Chlorogenic acid (CGA) enhances the expression of PPARγ2 during the differentiation process of mouse 3T3-L1 preadipocytes. Mouse 3T3-L1 preadipocytes were immunostained for PPARγ2 protein (green) (A), while nuclei were simultaneously revealed by DAPI staining (blue) (B). Colocalization is rendered in the merge panels (cyan) (C). Subcellular distribution of PPARγ2 and nuclei was analyzed by microscopic confocal analysis. (a) 0 days (630 ×); (b) 2 days (630 ×); (d) 8 days (630 ×). ((c) and (e)) The intensity of the green and blue fluorescence was quantified using ZEN 2 lite software. Data are shown as the means ± SD (n = 3). ^∗P < 0.05, ^∗∗P < 0.01, ^∗∗∗P < 0.001.

4. Discussion

RG is a full agonist of PPARγ, activates the PPARγ nuclear receptor, and is widely used as a therapeutic agent for type 2 diabetes. However, studies indicate that partial PPARγ agonists have lower risks of causing side effects (e.g., edema, fractures, and heart failure) relative to full PPARγ agonists, although they exhibit similar effects associated with insulin sensitivity. Therefore, it is necessary to identify safer and more effective partial PPARγ agonists [37, 38].

Many studies report that the CGA complex can be promoted as an active ingredient in the nutritional management of obesity [16, 39, 40]. In the present study, we investigated whether CGA could also affect preadipocyte differentiation through its lipid-lowering effect, as well as the molecular mechanism associated with CGA-mediated adipogenesis. We treated mouse 3T3-L1 preadipocytes with different doses of CGA, significant inhibition of 3T3-L1 cell viability in a time- and dose-dependent manner (Figure 1).

Lee et al. [41] reported changes in morphology of 3T3-L1 preadipocytes from a predifferentiation spindle-like shape to a round shape during early differentiate, with subsequent development of lipid droplets indicating preadipocyte differentiation into adipocytes and their accumulation signaling adipocyte maturity [42]. In the present study, ORO staining indicated that CGA promoted adipocyte differentiation, albeit to a lesser degree than that observed following RG treatment [Figure 2(A)(a)]. We found that the shape of the lipid droplets differed in the CGA-treated group relative to those in the RG-treated group (i.e., small and not ring-like) [Figure 2(A)(a, d)] and implying that lipid accumulation in the CGA-treated group differed from that in the RG-treated group. Moreover, this morphological change was consistent with those reported previously [40].

According to the biological processes associated with adipocyte differentiation, we evaluated the expression levels of Plin and Srebp, which comprise important factors related to lipid homeostasis in 3T3-L1 cells. Lipid droplets store a large amount of TAGs, thereby regulating the storage and hydrolysis of lipids in mammalian adipocytes. The stability of lipid droplets is dependent upon PLINs, the most well-known coat proteins embedded in the phospholipid monolayer of lipid droplets [43] and that bind to and stabilize newly formed lipid droplets in order to protect them from breakdown by HSL [34, 43]. Ruiz et al. [38] reported that SREBP1 levels are significantly elevated in obese patients and animal models of obesity and type 2 diabetes, with other studies indicating that SREBP1 contributes to hepatic lipid accumulation and insulin resistance. In the present study, we found that CGA treatment significantly enhanced Plin and Srebp1 expression as compared with levels in the control group, thereby contributing to lipid accumulation in 3T3-L1 cells. However, levels of both genes following CGA treatment were significantly lower than those in the RG-treated group (Figures 2(B) and 2(C)), suggesting increased lipid accumulation following RG treatment relative to that observed after CGA treatment.

Interestingly, Zheng et al. [39] demonstrated that CGA treatment decreased serum levels of TAG, a marker for lipid homeostasis, in mice, and that hepatic TAG concentrations were decreased by CGA + caffeine administration. Moreover, a previous study reported that CGA treatment decreased TAG levels in the liver and plasma of Sprague-Dawley rats on a high-energy diet [44]. In the present study, the TAG content of CGA-treated 3T3-L1 cells increased by only 12.25%, whereas TAG levels increased significantly by 101.02% following RG treatment relative to levels in the control group (Figure 3(a)). These results suggested that CGA treatment promoted adipocyte differentiation but had a weak effect on lipid accumulation in 3T3-L1 cells.

The Hsl gene is expressed in adipose tissue, where it hydrolyzes stored triglycerides to free fatty acids and mobilizes the stored lipids [45]. Therefore, HSL constitutes the rate-limiting enzyme in TAG catabolism, whereas DGAT1 is the key enzyme associated with TAG synthesis [17]. Figure 2(B) shows similar Plin expression between the CGA- and RG-treated groups during the differentiation process, whereas Hsl expression was lower in the CGA-treated group relative to that in the RG-treated group (Figure 3(b)). These results suggested that the rate of lipid degradation following CGA treatment was lower than that following RG treatment, contradicting the results of ORO and TAG staining (Figures 2(A) and 3(a)). However, it is worth noting that Dgat1 expression in the RG-treated group was ~1.5-fold higher than that in the CGA-treated group from the initial stage of differentiation to D8 and that Dgat1 expression in the CGA-treated group was similar to that in the control group. On D6 of differentiation, Dgat1 expression in the CGA-treated group was lower than that in the GW9662 group (Figure 3(c)), implying that lipid synthesis following CGA treatment was inhibited as compared with that following RG treatment. Additionally, during the primary differentiation stage, Srebp1 expression in the CGA-treated group was lower than that in the RG-treated group (Figure 3(c)). This might represent one of the mechanisms associated with the differences in the results of ORO staining observed between the CGA- and RG-treated groups and suggests that CGA intervention led to the accumulation of intracellular TAG during adipocyte differentiation, although to levels significantly lower than those in the RG-treated group.

Moreover, we observed that expression of key adipocyte-differentiation-related factors (Pref1, Pparg2, and Cebpb) changed during adipocyte differentiation. Our results agreed with a previous study reporting abundant Pref1 expression in preadipocytes but a dramatic decrease in these levels during adipocyte differentiation [46]. Moreover, constitutive expression of Pref1 in preadipocytes inhibits adipocyte differentiation [46]. PREF1 obstructs adipocyte differentiation by combining the promoter regions of Cebpb and Cebpd and inactivating C/EBPα and PPARγ [47]. Furthermore, Pref1 overexpression decreases adipocyte-marker expression [46], and dexamethasone-mediated inhibition of Pref1 expression in preadipocytes activates PPARγ and stimulates preadipocyte differentiation and maturation [48]. As an important transcription factor and master regulator of adipogenesis, PPARγ plays an important role in regulating the expression of genes involved in fatty acid β oxidation, lipid homeostasis, and controlling adipogenesis [49].

PPARγ has at least two subtypes: PPARγ1 is expressed in most tissues, and PPARγ2 is expressed specifically in adipose tissue [36]. C/EBPα shares a pathway with PPARγ associated with regulating preadipocyte differentiation, with C/EBPα activity dependent upon PPARγ status. Both proteins regulate the expression of activating protein (Ap)-2, Fas, and Hsl, as well as other factors related to preadipocyte differentiation [50]. Additionally, PPARγ promotes the transformation of cultured myoblasts into adipocytes, especially when coexpressed with C/EBPα [41]. During the early stage of adipocyte differentiation, Cebpb is highly expressed and initiates mitotic clonal expansion to enable entry of preadipose cells into the cell-proliferation cycle. After approximately two rounds of mitosis, cells exit this cycle and enter the differentiation stage, at which point C/EBPβ activates the expression of Pparg and other adipokines by binding to their promoter regions [51–54]. Additionally, C/EBPβ can also promote non-fat cell differentiation into adipocytes [55]; however, this requires PPARγ formation of a dimer with RXRα, which promotes transcriptional activity via binding to DNA [56]. PPARγ1 and PPARγ2 effectively stimulate adipocyte differentiation, although, under low-ligand (RXRα) concentrations, PPARγ2 stimulation of adipose-tissue formation is significantly stronger than that of PPARγ1 [57]. Moreover, Ren et al. [58] demonstrated that PPARγ2 rather than PPARγ1 plays a role in promoting cell differentiation.

In the present study, CGA and RG treatment, respectively, downregulated Pref1 expression and upregulated Pparg2 and Cebpb expression in all stages of 3T3-L1 cell differentiation and relative to levels observed in the control and GW9662-treated groups (Figures 4(a)–4(c)), whereas only minimal increases in Rxra levels were observed relative to controls (Figure 4(d)). These expression levels during adipocyte differentiation were consistent with those reported previously [46, 49, 51–54]. Notably, the effect of CGA treatment was more pronounced than that of RG treatment, with CGA treatment having a greater effect on Pref1 expression. These data suggested that the number of preadipocytes in the CGA- and RG-treated groups was lower than that in the two control groups and that the majority of these adipocytes were able to differentiate into mature adipocytes. This finding was consistent with the results of ORO staining (Figure 2(A)). Additionally, several studies reported that downregulating Plin, Srebp, Pparg, and Cebpa inhibits adipogenesis in 3T3-L1 preadipocytes [34, 54, 59–61]. The results of the present study indicated that CGA treatment promoted adipogenesis specifically by affecting activation of adipogenic transcription factors and regulating adipogenesis-related gene expression.

Besten et al. [62] reported that short-chain fatty acids (SCFAs) prevent and reverse HFD-induced obesity in mice via a PPARγ-dependent switch from lipid synthesis to fat oxidation. SCFAs also stimulate mitochondrial fatty acid oxidation by activating the uncoupling protein 2 (UCP2)-AMPK-acetyl-CoA carboxylase (ACC) pathway in 3T3-L1 preadipocytes. Moreover, activating or inhibiting PPARγ activity via the PPARγ agonist RG or the PPARγ antagonist GW9662 abolishes SCFA-induced increases in UCP2-pAMPK-pACC signaling [63]. In the present study, we observed significantly lower TAG accumulation in 3T3-L1 cells following CGA treatment relative to that following RG treatment; however, whether this was due to CGA-mediated activation of UCP2-pAMPK-pACC signaling to promote β oxidation of fatty acids remains unknown.

Analysis of PPARγ2 levels revealed significant increases in Pparg2 expression in both CGA- and RG-treated groups, and that in the GW9662-treated group was significantly lower, relative to that observed in the control during the course of adipocyte differentiation and especially on D4 (Figure 4(c)). Our analysis of PPARγ2 levels agreed with qPCR results (Figures 4(c), 5, and 6) and with those reported previously [17]. These findings supported a role for CGA in promoting adipocyte through PPARγ2 expression and activity.

Zheng et al. [39] reported that supplementation of culture medium with 0.2% CGA reduced hepatic Pparg expression in mice, and Ryohei et al. [64] demonstrated that 5% caffeine downregulated PPARγ levels; however, the major bioactive constituent of CGA in coffee extract showed no effect on Pparg expression at concentrations of 100 μM. These results were inconsistent with the findings reported in the present study. Notably, numerous studies reported results consistent with our findings [17, 22, 25]. Sanchez et al. [22] reported that CGA acted as either an insulin secretagogue or a PPARα/γ dual agonist, and Ghadieh et al. [25] demonstrated that CGA/chromium supplementation alleviates insulin resistance. Additionally, our previous in vivo study [14] showed that supplementation with either low or high doses of CGA (20 and 90 mg/kg, respectively) significantly increased adipose-tissue PPARγ2 mRNA and protein levels, with these levels of CGA supplementation equivalent to physiological concentrations present in humans [17]. Moreover, Du et al. [65] demonstrated that intravenous injection of a 5-fold higher level of CGA than the recommended daily amount induced inflammation reactions and oxidative-stress injury in rats, with these findings supporting our use of 20 μM CGA in the present study. These findings suggest that the CGA concentration used in the present study was significantly lower than those of previous studies. Furthermore, the majority of CGA is hydrolyzed to caffeic acid and quinic acid before being absorbed in the gastrointestinal tract by gut microbiota esterases in both the small and large intestine [63]. Therefore, differences in dosage, CGA hydrolysis, or differentiation conditions might have contributed to inconsistencies in results. Nevertheless, our findings showed that CGA treatment activated PPARγ to a degree similar to RG treatment, potentially explaining the ability of CGA to increase insulin sensitivity and inhibit chronic inflammation caused by obesity [17, 21, 22, 25].

Previous studies reported strong links between PPARγ2 and the inflammatory response associated with obesity. PPARγ2 inhibits the inflammatory response via the NF-κB, Janus kinase-signal transducers and activators of transcription (STAT), AP-1, and nuclear factor of activated T cell pathways [66, 67]. As early as 1998, Ricote et al. [68] demonstrated that activation of PPARγ results in reduced transcriptional activity of cytokine-induced inflammation-associated factors, such as Ap-1, Nfkb, and Stat genes in mouse myeloid progenitor cells. Additionally, PPARγ reportedly plays an important role in improving insulin sensitivity [69], with clinical studies showing improvements in metabolic disorders and reduced inflammatory responses in type 2 diabetes patients treated with the PPARγ agonist RG within 6 months after receiving coronary artery intervention [70]. In the present study, CGA treatment promoted preadipocyte differentiation by activating PPAPγ2 in a similar manner to RG treatment, although RG treatment promoted a greater increase in lipid accumulation relative to that observed following CGA treatment. These results implied that CGA prevented lipid accumulation, even in the presence of activated PPAPγ2, suggesting its potential efficacy as a PPARγ agonist for clinical application.

5. Conclusions

This represents the first validation that CGA constitutes a PPAPγ2 agonist capable of effectively stimulating 3T3-L1 preadipocyte differentiation. However, our findings showed that CGA acted differently from RG in the area of fat metabolism during adipocyte differentiation and that TAG content was significantly higher in the RG-treated group relative to that in the CGA-treated group. This might be due to CGA enhancing lipolysis but not lipid synthesis, resulting in decreased lipid accumulation prior to preadipocyte differentiation. These data indicated that CGA represents a novel PPARγ2 agonist different from RG; however, further study of the regulation mechanism associated with CGA-mediated activity on lipid metabolism is necessary to provide insight to its potential application for preventing insulin resistance and hyperglycemia.

Data Availability

All the data are available from Professor Zheng Wang ([email protected]) upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Shu-guang Peng and Yi-lin Pang are equal contributors.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (31071531) and the Foundation of the Research Institute of Hunan Tobacco Science (15-17Aa04).

References

D. M. Nathan, “Diabetes: advances in diagnosis and treatment,” The Journal of the American Medical Association, vol. 314, no. 10, pp. 1052–1062, 2015.
View at: Publisher Site | Google Scholar
J. Ye, “Challenges in drug discovery for thiazolidinedione substitute,” Acta Pharmaceutica Sinica B (APSB), vol. 1, no. 3, pp. 137–142, 2011.
View at: Publisher Site | Google Scholar
K. Ogurtsova, J. da Rocha Fernandes, Y. Huang et al., “IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040,” Diabetes Research and Clinical Practice, vol. 128, pp. 40–50, 2017.
View at: Publisher Site | Google Scholar
X. Song, H. Jia, Y. Jiang et al., “Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis,” Scientific Reports, vol. 5, 2015.
View at: Google Scholar
S. Chatterjee, K. Khunti, and M. J. Davies, “Type 2 diabetes,” The Lancet, vol. 389, no. 10085, pp. 2239–2251, 2017.
View at: Publisher Site | Google Scholar
S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” The New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007.
View at: Publisher Site | Google Scholar
W. Wei, X. Wang, M. Yang, L. C. Smith, and P. C. Dechow, “PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss,” Cell Metabolism, vol. 11, no. 6, pp. 503–516, 2010.
View at: Publisher Site | Google Scholar
T. J. Orchard, “The effect of rosiglitazone on overweight subjects with type 1 diabetes,” Diabetes Care, vol. 29, no. 3, pp. 746-747, 2006.
View at: Google Scholar
K.-H. Zhang, Q. Huang, X.-P. Dai et al., “Effects of the peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus,” Clinical Pharmacology and Therapeutics, vol. 50, no. 9, pp. 1022–1030, 2010.
View at: Publisher Site | Google Scholar
Y. Lu, D. Ma, W. Xu, S. Shao, and X. Yu, “Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: a meta-analysis,” Journal of Diabetes Investigation, vol. 6, no. 1, pp. 78–86, 2015.
View at: Publisher Site | Google Scholar
I. Schreiber, G. Dörpholz, C.-E. Ott et al., “BMPs as new insulin sensitizers: Enhanced glucose uptake in mature 3T3-L1 adipocytes via PPARγ and GLUT4 upregulation,” Scientific Reports, vol. 7, no. 1, 2017.
View at: Google Scholar
Y. Toyota, S. Nomura, M. Makishima, Y. Hashimoto, and M. Ishikawa, “Structure-activity relationships of rosiglitazone for peroxisome proliferator-activated receptor gamma transrepression,” Bioorganic & Medicinal Chemistry Letters, vol. 27, no. 12, pp. 2776–2780, 2017.
View at: Publisher Site | Google Scholar
M. N. Clifford, “Miscellaneous phenols in foods and beverages - Nature, occurrence and dietary burden,” Journal of the Science of Food and Agriculture, vol. 80, no. 7, pp. 1126–1137, 2000.
View at: Publisher Site | Google Scholar
A. A. Adedapo, B. O. Adeoye, M. O. Sofidiya, and A. A. Oyagbemi, “Antioxidant, antinociceptive and anti-inflammatory properties of the aqueous and ethanolic leaf extracts of Andrographis paniculata in some laboratory animals,” Journal of Basic and Clinical Physiology and Pharmacology, vol. 26, no. 4, pp. 327–334, 2015.
View at: Publisher Site | Google Scholar
S. Ahuja, S. Kohli, S. Krishnan, D. Dogra, D. Sharma, and V. Rani, “Curcumin: A potential therapeutic polyphenol, prevents noradrenaline- induced hypertrophy in rat cardiac myocytes,” Journal of Pharmacy and Pharmacology, vol. 63, no. 12, pp. 1604–1612, 2011.
View at: Publisher Site | Google Scholar
N. Tajik, M. Tajik, I. Mack, and P. Enck, “The potential effects of chlorogenic acid, the main phenolic components in coffee, on health: a comprehensive review of the literature,” European Journal of Nutrition, vol. 56, no. 7, pp. 2215–2244, 2017.
View at: Publisher Site | Google Scholar
S.-L. Liu, B.-J. Peng, Y.-L. Zhong, Y.-L. Liu, Z. Song, and Z. Wang, “Effect of 5-caffeoylquinic acid on the NF-κB signaling pathway, peroxisome proliferator-activated receptor gamma 2, and macrophage infiltration in high-fat diet-fed Sprague-Dawley rat adipose tissue,” Food & Function, vol. 6, no. 8, pp. 2779–2786, 2015.
View at: Publisher Site | Google Scholar
R. Jiang, J. M. Hodgson, E. Mas, K. D. Croft, and N. C. Ward, “Chlorogenic acid improves ex vivo vessel function and protects endothelial cells against HOCl-induced oxidative damage, via increased production of nitric oxide and induction of Hmox-1,” The Journal of Nutritional Biochemistry, vol. 27, pp. 53–60, 2016.
View at: Publisher Site | Google Scholar
S. J. Deka, S. Gorai, D. Manna, and V. Trivedi, “Evidence of PKC binding and translocation to explain the anticancer mechanism of chlorogenic acid in breast cancer cells,” Current Molecular Medicine, vol. 17, no. 1, pp. 79–89, 2017.
View at: Publisher Site | Google Scholar
Z. Zhang, D. Wang, S. Qiao et al., “Metabolic and microbial signatures in rat hepatocellular carcinoma treated with caffeic acid and chlorogenic acid,” Scientific Reports, vol. 7, no. 1, 2017.
View at: Google Scholar
N. Xue, Q. Zhou, M. Ji et al., “Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype,” Scientific Reports, vol. 7, no. 1, 2017.
View at: Publisher Site | Google Scholar
M. B. Sanchez, E. Miranda-Perez, J. C. G. Verjan, M. de los Angeles Fortis Barrera, J. Perez-Ramos, and F. J. Alarcon-Aguilar, “Potential of the chlorogenic acid as multitarget agent: Insulin-secretagogue and PPAR α/γ dual agonist,” Biomedicine & Pharmacotherapy, vol. 94, pp. 169–175, 2017.
View at: Publisher Site | Google Scholar
Z. Hakkou, A. Maciuk, V. Leblais et al., “Antihypertensive and vasodilator effects of methanolic extract of Inula viscosa: Biological evaluation and POM analysis of cynarin, chlorogenic acid as potential hypertensive,” Biomedicine & Pharmacotherapy, vol. 93, pp. 62–69, 2017.
View at: Publisher Site | Google Scholar
O. Palócz, E. Pászti-Gere, P. Gálfi, and O. Farkas, “Chlorogenic acid combined with lactobacillus plantarum 2142 reduced LPS-induced intestinal inflammation and oxidative stress in IPEC-J2 cells,” PLoS ONE, vol. 11, no. 11, 2016.
View at: Google Scholar
H. E. Ghadieh, Z. N. Smiley, M. W. Kopfman, M. G. Najjar, M. J. Hake, and S. M. Najjar, “Chlorogenic acid/chromium supplement rescues diet-induced insulin resistance and obesity in mice,” Journal of Nutrition and Metabolism, vol. 12, no. 1, 2015.
View at: Google Scholar
G. Martínez, M. Regente, S. Jacobi, M. Del Rio, M. Pinedo, and L. de la Canal, “Chlorogenic acid is a fungicide active against phytopathogenic fungi,” Pesticide Biochemistry and Physiology, vol. 140, pp. 30–35, 2017.
View at: Publisher Site | Google Scholar
L. Wang, C. Bi, H. Cai et al., “The therapeutic effect of chlorogenic acid against Staphylococcus aureus infection through sortase A inhibition,” Frontiers in Microbiology, vol. 6, 2015.
View at: Google Scholar
D. Wu, C. Bao, L. Li et al., “Chlorogenic acid protects against cholestatic liver injury in rats,” Journal of Pharmacological Sciences, vol. 129, no. 3, pp. 177–182, 2015.
View at: Publisher Site | Google Scholar
H. Ye, J. Jin, L. Jin, Y. Chen, Z. Zhou, and Z. Li, “Chlorogenic Acid Attenuates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting TLR4/NF-κB Signal Pathway,” Inflammation, vol. 40, no. 2, pp. 523–529, 2017.
View at: Publisher Site | Google Scholar
Y. Mikami and T. Yamazawa, “Chlorogenic acid, a polyphenol in coffee, protects neurons against glutamate neurotoxicity,” Life Sciences, vol. 139, pp. 69–74, 2015.
View at: Publisher Site | Google Scholar
J. J. Park, S. J. Hwang, J.-H. Park, and H.-J. Lee, “Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1α/AKT pathway,” Cellular Oncology, vol. 38, no. 2, pp. 111–118, 2015.
View at: Publisher Site | Google Scholar
S. Q. Zheng, X. B. Huang, T. K. Xing, A. J. Ding, G. S. Wu, and H. R. Luo, “Chlorogenic acid extends the lifespan of caenorhabditis elegans via insulin/IGF-1 signaling pathway,” Journal of Gerontology Series A Biological Sciences and Medical Sciences, vol. 72, pp. 464–472, 2017.
View at: Google Scholar
A.-S. Cho, S.-M. Jeon, M.-J. Kim et al., “Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice,” Food and Chemical Toxicology, vol. 48, no. 3, pp. 937–943, 2010.
View at: Publisher Site | Google Scholar
B.-C. Jang, “Artesunate inhibits adipogeneis in 3T3-L1 preadipocytes by reducing the expression and/or phosphorylation levels of C/EBP-α, PPAR-γ, FAS, perilipin A, and STAT-3,” Biochemical and Biophysical Research Communications, vol. 474, no. 1, pp. 220–225, 2016.
View at: Publisher Site | Google Scholar
R. Ruiz, V. Jideonwo, M. Ahn et al., “Sterol regulatory element-binding protein-1 (SREBP-1) is required to regulate glycogen synthesis and gluconeogenic gene expression in mouse liver,” The Journal of Biological Chemistry, vol. 289, no. 9, pp. 5510–5517, 2014.
View at: Publisher Site | Google Scholar
S. Tyagi, P. Gupta, A. S. Saini, C. Kaushal, and S. Sharma, “The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases,” Journal of Advanced Pharmaceutical Technology & Research, vol. 2, no. 4, pp. 236–240, 2011.
View at: Publisher Site | Google Scholar
R. M. Lago, P. P. Singh, and R. W. Nesto, “Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials,” The Lancet, vol. 370, no. 9593, pp. 1129–1136, 2007.
View at: Publisher Site | Google Scholar
R. Agrawal, P. Jain, and S. N. Dikshit, “Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist,” Mini-Reviews in Medicinal Chemistry, vol. 12, no. 2, pp. 87–97, 2012.
View at: Publisher Site | Google Scholar
G. Zheng, Y. Qiu, Q.-F. Zhang, and D. Li, “Chlorogenic acid and caffeine in combination inhibit fat accumulation by regulating hepatic lipid metabolism-related enzymes in mice,” British Journal of Nutrition, vol. 112, no. 6, pp. 1034–1040, 2014.
View at: Publisher Site | Google Scholar
D. De Souza Marinho Do Nascimento, R. M. Oliveira, R. B. G. Camara et al., “Baccharis trimera (Less.) DC exhibits an anti-adipogenic effect by inhibiting the expression of proteins involved in adipocyte differentiation,” Molecules, vol. 22, no. 6, 2017.
View at: Google Scholar
E. Hu, P. Tontonoz, and B. M. Spiegelman, “Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPα,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 92, no. 21, pp. 9856–9860, 1995.
View at: Publisher Site | Google Scholar
H. Lee, J. Kim, J. Y. Park, K. S. Kang, J. H. Park, and G. S. Hwang, “Processed panax ginseng, sun ginseng, inhibits the differentiation and proliferation of 3T3-L1 preadipocytes and fat accumulation in caenorhabditis elegans,” Journal of Ginseng Research, vol. 41, no. 3, pp. 257–267, 2017.
View at: Publisher Site | Google Scholar
T. Fujimoto, Y. Ohsaki, J. Cheng, M. Suzuki, and Y. Shinohara, “Lipid droplets: a classic organelle with new outfits,” Histochemistry and Cell Biology, vol. 130, no. 2, pp. 263–279, 2008.
View at: Publisher Site | Google Scholar
K. Huang, X.-C. Liang, Y.-L. Zhong, W.-Y. He, and Z. Wang, “5-Caffeoylquinic acid decreases diet-induced obesity in rats by modulating PPARα and LXRα transcription,” Journal of the Science of Food and Agriculture, vol. 95, no. 9, pp. 1903–1910, 2015.
View at: Publisher Site | Google Scholar
C. W. Liew, J. Boucher, J. K. Cheong et al., “Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance,” Nature Medicine, vol. 19, no. 2, pp. 217–226, 2013.
View at: Publisher Site | Google Scholar
C. M. Smas and H. S. Sul, “Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation,” Cell, vol. 73, no. 4, pp. 725–734, 1993.
View at: Publisher Site | Google Scholar
C. S. Hudak and H. S. Sul, “Pref-1, a gatekeeper of adipogenesis,” Frontiers in Endocrinology, vol. 4, 2013.
View at: Google Scholar
H. S. Sul, C. Smas, B. Mei, and L. Zhou, “Function of pref-1 as an inhibitor of adipocyte differentiation,” International Journal of Obesity, vol. 24, pp. S15–S19, 2000.
View at: Publisher Site | Google Scholar
J. Jang, Y. Jung, S. Chae et al., “Gangjihwan, a polyherbal composition, inhibits fat accumulation through the modulation of lipogenic transcription factors SREBP1C, PPARγ and C/EBPα,” Journal of Ethnopharmacology, vol. 210, pp. 10–22, 2018.
View at: Publisher Site | Google Scholar
E. D. Rosen, C. H. Hsu, X. Wang et al., “C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway,” Genes & Development, vol. 16, no. 1, pp. 22–26, 2002.
View at: Publisher Site | Google Scholar
R. Herrera, H. S. Ro, G. S. Robinson, K. G. Xanthopoulos, and B. M. Spiegelman, “A direct role for C/EBP and the AP-I-binding site in gene expression linked to adipocyte differentiation,” Molecular and Cellular Biology, vol. 9, no. 12, pp. 5331–5339, 1989.
View at: Publisher Site | Google Scholar
R. J. Christy, K. H. Kaestner, D. E. Geiman, and M. Daniel Lane, “CCAAT/enhancer binding protein gene promoter: Binding of nuclear factors during differentiation of 3T3-L1 preadipocytes,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 88, no. 6, pp. 2593–2597, 1991.
View at: Publisher Site | Google Scholar
C.-S. Hwang, S. Mandrup, O. A. MacDougald, D. E. Geiman, and M. D. Lane, “Transcriptional activation of the mouse obese (ob) gene by CCAAT/enhancer binding protein α,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 93, no. 2, pp. 873–877, 1996.
View at: Publisher Site | Google Scholar
K. M. Sprott, M. J. Chumley, J. M. Hanson, and R. T. Dobrowsky, “Decreased activity and enhanced nuclear export of CCAAT-enhancer-binding protein β during inhibition of adipogenesis by ceramide,” Biochemical Journal, vol. 365, no. 1, pp. 181–191, 2002.
View at: Publisher Site | Google Scholar
Z. Wu, Y. Xie, N. L. Bucher, and S. R. Farmer, “Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis,” Genes & Development, vol. 9, pp. 2350–2363, 1995.
View at: Google Scholar
J. L. Oberfield, J. L. Collins, C. P. Holmes et al., “A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 96, no. 11, pp. 6102–6106, 1999.
View at: Publisher Site | Google Scholar
E. Mueller, S. Drori, A. Aiyer et al., “Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor γ isoforms,” The Journal of Biological Chemistry, vol. 277, no. 44, pp. 41925–41930, 2002.
View at: Publisher Site | Google Scholar
D. Ren, T. N. Collingwood, E. J. Rebar, A. P. Wolffe, and H. S. Camp, “PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis,” Genes & Development, vol. 16, pp. 27–32, 2002.
View at: Google Scholar
A. M. Rashid, K. Lu, Y. M. Yip, and D. Zhang, “Averrhoa carambola L. peel extract suppresses adipocyte differentiation in 3T3-L1 cells,” Food & Function, vol. 7, no. 2, pp. 881–892, 2016.
View at: Publisher Site | Google Scholar
L. Y. Cheong, S. Suk, N. R. Thimmegowda et al., “Hirsutenone directly targets PI3K and ERK to inhibit adipogenesis in 3T3-L1 preadipocytes,” Journal of Cellular Biochemistry, vol. 116, no. 7, pp. 1361–1370, 2015.
View at: Publisher Site | Google Scholar
K. Kowalska, A. Olejnik, J. Rychlik, and W. Grajek, “Cranberries (Oxycoccus quadripetalus) inhibit adipogenesis and lipogenesis in 3T3-L1 cells,” Food Chemistry, vol. 148, pp. 246–252, 2014.
View at: Publisher Site | Google Scholar
G. Den Besten, A. Bleeker, A. Gerding et al., “Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARgamma-dependent switch from lipogenesis to fat oxidation,” Diabetes, vol. 64, no. 7, pp. 2398–2408, 2015.
View at: Publisher Site | Google Scholar
Y. Konishi and S. Kobayashi, “Transepithelial transport of chlorogenic acid, caffeic acid, and their colonic metabolites in intestinal caco-2 cell monolayers,” Journal of Agricultural and Food Chemistry, vol. 52, pp. 2518–2526, 2004.
View at: Google Scholar
R. Aoyagi, M. Funakoshi-Tago, Y. Fujiwara, and H. Tamura, “Coffee inhibits adipocyte differentiation via inactivation of PPARγ,” Biological & Pharmaceutical Bulletin, vol. 37, no. 11, pp. 1820–1825, 2014.
View at: Publisher Site | Google Scholar
W.-Y. Du, C. Chang, Y. Zhang et al., “High-dose chlorogenic acid induces inflammation reactions and oxidative stress injury in rats without implication of mast cell degranulation,” Journal of Ethnopharmacology, vol. 147, no. 1, pp. 74–83, 2013.
View at: Publisher Site | Google Scholar
R. B. Clark, D. Bishop-Bailey, T. Estrada-Hernandez, T. Hla, L. Puddington, and S. J. Padula, “The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses,” The Journal of Immunology, vol. 164, no. 3, pp. 1364–1371, 2000.
View at: Publisher Site | Google Scholar
H. Lee, W. Shi, P. Tontonoz et al., “Role for peroxisome proliferator-activated receptor α in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 interleukin-8 by endothelial cells,” Circulation Research, vol. 87, no. 6, pp. 516–521, 2000.
View at: Publisher Site | Google Scholar
M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998.
View at: Publisher Site | Google Scholar
Z.-Y. Li, J. Song, S.-L. Zheng et al., “Adipocyte Metrnl Antagonizes Insulin Resistance Through PPARγ Signaling,” Diabetes, vol. 64, no. 12, pp. 4011–4022, 2015.
View at: Publisher Site | Google Scholar
G. Wang, J. Wei, Y. Guan, N. Jin, J. Mao, and X. Wang, “Peroxisome proliferator-activated receptor-γ agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty,” Metabolism - Clinical and Experimental, vol. 54, no. 5, pp. 590–597, 2005.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2018 Shu-guang Peng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

2046

Downloads

1665

Citations